2026-04112RuleWallet

DEA Schedules Weird Benzos: Five Designer Drugs Hit Schedule I

Published Date: 3/2/2026

Rule

Summary

Starting April 1, 2026, the DEA is making it official: clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam are now permanently in Schedule I, meaning they’re considered dangerous with no accepted medical use. This affects anyone who makes, sells, or uses these drugs, bringing strict rules and penalties. The move also helps the U.S. follow international drug control agreements.

Analyzed Economic Effects

6 provisions identified: 0 benefits, 6 costs, 0 mixed.

Five designer benzodiazepines now Schedule I

Starting April 1, 2026, clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam (and their salts/isomers) are permanently placed in Schedule I of the Controlled Substances Act. That means these substances are legally treated as having high abuse potential, no accepted medical use in the United States, and are subject to Schedule I controls.

Unauthorized possession and handling unlawful

Possession or handling of clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam in any manner not authorized by the CSA is unlawful as of April 1, 2026, and may subject the person to administrative, civil, and/or criminal sanctions. Retail sales to the general public of Schedule I substances are not allowed under the CSA.

Registration required to handle these drugs

Any person who handles (manufactures, distributes, imports/exports, engages in research, conducts instructional activities or chemical analysis with, or possesses) these five substances must be registered with DEA under 21 U.S.C. 822, 823, 957, and 958 and comply with 21 CFR parts 1301 and 1312. Anyone currently handling these substances who is not registered must submit a registration application and may not continue to handle them unless DEA approves the application.

Research allowed but requires DEA permission

Placement in Schedule I does not preclude academic or scientific research, but anyone who wishes to conduct research on clonazolam, diclazepam, etizolam, flualprazolam, or flubromazolam must seek and obtain DEA permission and appropriate registration before handling them.

Schedule I regulatory controls apply (security, records)

As Schedule I substances, clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam must be handled under Schedule I security requirements, labeling and packaging rules, quotas for manufacture, biennial inventories, recordkeeping and reporting, DEA order-form requirements, and import/export controls per the CSA and implementing CFR parts (e.g., 21 CFR parts 1301, 1302, 1303, 1304, 1312, and 1317).

Surrender or transfer of existing stocks before effective date

Any person unwilling or unable to obtain a Schedule I registration must surrender or transfer all quantities of these five substances to a DEA-registered person before the effective date of the final scheduling action, and any disposal must follow 21 CFR part 1317 and applicable laws. The effective date for the permanent scheduling is April 1, 2026.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Rule Effective
3/2/2026
4/1/2026

Department and Agencies

Department
Independent Agency
Agency
Justice Department
Drug Enforcement Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in